Gemelli Biotech has highlighted new implications from a peer-reviewed study linking intestinal sulfide overproduction with distinctive changes in gene expression within the human small bowel. Announced on October 30, 2026, the findings come from research led by the Medically Associated Science and Technology programme at Cedars-Sinai, which analysed intestinal tissue samples from 85 participants and used Gemelli Biotech’s proprietary gas chromatography technology to measure hydrogen sulfide and methane in breath samples.
The study, published online in the American Society for Microbiology journal mSystems on June 29, 2026, found that intestinal sulfide overproduction was associated with broader changes in intestinal gene activity than two related microbial conditions: small intestinal bacterial overgrowth and intestinal methanogen overgrowth. The affected pathways included mitochondrial energy production, oxidative balance, immune signalling and processes associated with intestinal fluid regulation.
The findings provide biological evidence supporting the investigation of intestinal sulfide overproduction as a distinct host-microbial condition. However, the study was exploratory and did not demonstrate that breath testing improves patient outcomes, identifies an effective treatment or can independently diagnose irritable bowel syndrome. Its commercial relevance to Gemelli Biotech lies in strengthening the scientific rationale for measuring hydrogen sulfide alongside hydrogen and methane.
What did the Cedars-Sinai study reveal about intestinal sulfide overproduction and small-bowel gene expression?
The investigation examined tissue obtained from participants in the REIMAGINE research programme, which studies the intestinal microbiome and its relationship with human biological processes. Researchers selected 85 individuals undergoing upper gastrointestinal endoscopy who had the required breath test, duodenal aspirate culture and biopsy information. The study then compared gene-expression patterns across patients classified according to different microbial conditions.
Of the 85 participants, 46 met the study’s definition of intestinal sulfide overproduction, based on fasting breath hydrogen sulfide concentrations of at least 1.5 parts per million. Twenty-two were classified as having intestinal methanogen overgrowth, while 21 met the study’s culture-based criteria for small intestinal bacterial overgrowth. These categories could overlap, meaning that some individuals had more than one microbial condition.
Researchers used RNA sequencing to examine which genes were expressed at higher or lower levels in the intestinal tissue. The analysis identified a broader pattern of altered gene expression among participants with elevated hydrogen sulfide than among those classified primarily by methane production or culture-defined bacterial overgrowth. Many of the affected genes were associated with cellular metabolism, oxidative stress and intestinal physiology.
The findings were particularly notable when participants with isolated intestinal sulfide overproduction were compared with individuals negative for all three conditions. In that analysis, researchers identified 132 differentially expressed genes using the study’s exploratory statistical thresholds. A more stringent significance threshold reduced the corresponding count, illustrating how the number of identified genes depends on the analytical criteria.
The study therefore identifies an association between elevated breath hydrogen sulfide and host intestinal biology. It does not establish that every patient with intestinal sulfide overproduction has the same molecular profile or that the identified gene changes cause gastrointestinal symptoms.
Why are intestinal sulfide overproduction, bacterial overgrowth and methanogen overgrowth being investigated as separate conditions?
Small intestinal bacterial overgrowth, or SIBO, is generally associated with excessive or altered bacterial populations in the small intestine. Intestinal methanogen overgrowth, known as IMO, involves increased activity of methane-producing microorganisms, which belong principally to the domain Archaea rather than bacteria. Intestinal sulfide overproduction, or ISO, describes a state associated with elevated hydrogen sulfide production.
These conditions can produce overlapping gastrointestinal complaints, including abdominal pain, bloating and altered bowel habits. However, previous microbiome research has suggested that their relationships with symptoms may differ. Methane production is commonly associated with constipation, while elevated hydrogen sulfide has been linked with diarrhoea and greater gastrointestinal symptom burden in selected populations.
The new transcriptomics study investigated whether these differences extend beyond microbial composition into the intestinal cells themselves. If microbial conditions are associated with different host responses, grouping them together may obscure biologically relevant distinctions. This could influence future research into mechanisms and treatment selection.
The researchers reported minimal overlap in differentially expressed genes between the isolated ISO, SIBO and IMO groups. No single differentially expressed gene was shared across all three isolated conditions under the reported comparisons. The finding suggests that the corresponding intestinal environments may be associated with different molecular responses.
However, the absence of shared genes in a relatively small exploratory analysis does not prove that the conditions are completely independent or mutually exclusive. Microbial communities interact, patients can meet criteria for several conditions simultaneously, and larger studies may identify additional overlapping pathways. The results support biological differentiation while leaving substantial uncertainty about how best to use that distinction clinically.
How did hydrogen sulfide measurements help identify changes in mitochondrial and oxidative stress pathways?
Hydrogen sulfide is produced through several biological processes, including microbial metabolism and endogenous cellular pathways. At appropriate concentrations, it can participate in physiological signalling, while excessive exposure may interfere with cellular functions. Its effects depend on concentration, location and the ability of tissues to metabolise the compound.
The Cedars-Sinai investigators identified changes in genes associated with mitochondrial respiration and oxidative balance among participants with elevated breath hydrogen sulfide. Mitochondria are involved in producing cellular energy, making disturbances in their function potentially relevant to intestinal epithelial activity. Alterations in related pathways may influence how cells respond to metabolic stress.
The research identified increased expression of CYP1A1 and changes involving several metallothionein genes associated with oxidative stress responses. It also reported reduced expression of SLC7A11, a gene involved in cellular antioxidant regulation and processes relevant to ferroptosis. These findings provide molecular clues about how an intestinal environment associated with elevated sulfide might affect host cells.
However, the study did not demonstrate that hydrogen sulfide directly caused each observed gene-expression change. Microbial activity, inflammation, diet and other factors may influence both breath gases and intestinal gene regulation. The associations therefore require further mechanistic investigation before specific causal pathways can be established.
The findings are relevant to the scientific rationale for measuring hydrogen sulfide because they connect a non-invasive breath measurement with biological changes detected in intestinal tissue. Nevertheless, detecting an association is different from establishing that a breath concentration can accurately identify an individual patient’s molecular state.
Why were changes in SLC7A11, CYP1A1 and intestinal fluid regulation important to the researchers?
The identification of SLC7A11 was relevant because the gene participates in maintaining cellular antioxidant capacity. Its reduced expression can influence pathways involved in oxidative stress and iron-dependent cellular injury under certain biological conditions. Researchers observed lower SLC7A11 expression in comparisons involving intestinal sulfide overproduction, making it a candidate for further mechanistic investigation.
CYP1A1 was another prominent finding. The gene encodes an enzyme involved in the metabolism of several compounds and can be influenced by environmental and metabolic conditions. Increased expression in the ISO-associated tissue samples suggests changes in cellular responses to the intestinal chemical environment.
The study also identified changes involving genes associated with intestinal transport, fluid regulation and neuromuscular signalling. These processes can influence the movement of water and contents through the gastrointestinal tract. The investigators considered the findings potentially relevant to mechanisms associated with diarrhoea-predominant irritable bowel syndrome.
However, the study did not demonstrate that particular gene changes directly produced diarrhoea or another symptom. The investigators measured gene expression in intestinal tissue rather than conducting an intervention that modified the identified genes. Functional experiments would be needed to establish whether the observed molecular differences cause changes in intestinal motility or secretion.
This distinction matters because transcriptomics can identify biological associations without establishing their functional consequences. A gene that is expressed differently in one group may be responding to an underlying condition rather than driving that condition. Translating these findings into clinical applications will require evidence connecting molecular activity with measurable patient outcomes.
What did the animal experiments reveal about hydrogen-sulfide-producing bacteria and intestinal biology?
The human tissue investigation was complemented by animal experiments examining the effects of selected hydrogen-sulfide-producing bacteria. Researchers administered bacterial strains to rats and analysed gene-expression changes in intestinal tissue. The objective was to investigate whether microbial exposure could reproduce aspects of the molecular patterns observed among human participants with intestinal sulfide overproduction.
Some of the animal experiments demonstrated changes involving mitochondrial respiration, oxidative balance and immune-related pathways. These findings were partially consistent with the human transcriptomics results, strengthening the biological rationale for investigating microbial hydrogen sulfide as a contributor to the observed patterns.
However, the animal findings were not uniform across every bacterial strain. Certain experiments produced limited or different effects, suggesting that microbial characteristics and experimental conditions influence the intestinal response. The researchers also identified limitations relating to bacterial strain differences and the ability to classify animals according to breath hydrogen sulfide measurements.
The partial agreement between human and animal findings provides mechanistic support but does not establish a complete causal explanation. Laboratory animal models differ from human intestinal environments in microbial composition, physiology and exposure conditions. Results from such models must therefore be interpreted alongside the observational human evidence.
The combined research supports continued investigation of the relationship between microbial sulfide production and intestinal cell function. It does not establish that eliminating particular bacteria will reverse the identified gene changes or improve symptoms in affected patients.
How does Gemelli Biotech’s Trio-Smart technology measure hydrogen sulfide differently from conventional two-gas breath testing?
Gemelli Biotech’s Trio-Smart is an at-home breath testing service designed to measure hydrogen, methane and hydrogen sulfide. Conventional gastrointestinal breath testing has historically concentrated on hydrogen and methane, which provide indirect information about microbial fermentation and methanogenic activity. Adding hydrogen sulfide measurement extends the range of gases available for clinical interpretation.
The technology uses gas chromatography to analyse breath samples collected according to the testing protocol. Gemelli Biotech processes samples through its central laboratory, which operates under Clinical Laboratory Improvement Amendments certification. The company says the service is available across the United States through physician ordering and patient-directed access.
The Cedars-Sinai study used Gemelli Biotech’s proprietary gas chromatography technology to measure hydrogen sulfide and methane in fasting breath samples. That methodological contribution is relevant because the research linked measured gas concentrations with gene-expression information from intestinal biopsies. However, the study’s single fasting-sample research method should not be treated as identical to every component of the commercial Trio-Smart testing protocol.
The study also used duodenal aspirate culture to classify SIBO rather than relying exclusively on hydrogen breath measurements. This distinction matters because the researchers were comparing different biological classifications using different diagnostic approaches. Their findings should not be interpreted as a direct validation of all three clinical classifications through the commercial breath test alone.
Trio-Smart is a laboratory-developed testing service rather than an FDA-approved diagnostic device under a specific marketing authorisation established by this study. Its clinical interpretation must therefore remain consistent with the assay’s validated characteristics and the available scientific evidence. The October announcement does not establish a new FDA approval or regulatory clearance.
Why do the study’s sample size and participant characteristics limit broader clinical conclusions?
The 85 participants were selected from individuals undergoing upper gastrointestinal endoscopy, meaning the study population was not a random sample of everyone experiencing irritable bowel syndrome symptoms. The average age was approximately 59 years, and most participants were White. These characteristics may influence how confidently the findings can be applied to younger or more diverse patient populations.
The relatively small numbers in the isolated microbial-condition groups create another limitation. Only 10 participants were classified as having isolated methanogen overgrowth, while 19 were negative for all three conditions. Comparisons involving such groups may lack statistical power to detect smaller but biologically meaningful differences.
The researchers acknowledged that larger studies are needed to validate their findings. They also identified the importance of examining the microbiome itself using more detailed sequencing approaches to connect specific microorganisms with host gene-expression changes. Such research could help determine whether the observed molecular patterns arise from particular microbial communities or broader intestinal conditions.
Another issue concerns the thresholds used to classify intestinal sulfide overproduction. The study examined different hydrogen sulfide cutoffs, including 1.5 and 2.0 parts per million, and reported that the number and pattern of altered genes varied with the comparison. These research thresholds should not automatically be interpreted as universally validated clinical diagnostic boundaries.
The findings are therefore useful for generating biological hypotheses but insufficient to establish a definitive molecular classification system for routine practice. Independent validation would be needed before transcriptomics patterns could support treatment decisions or determine which patients should receive particular interventions.
Could the study strengthen the clinical case for distinguishing hydrogen sulfide from methane and hydrogen in gastrointestinal diagnosis?
The research supports the proposition that elevated hydrogen sulfide is associated with intestinal biology that differs from conditions identified through methane production or bacterial culture. This adds mechanistic evidence to earlier investigations linking different breath gases with particular gastrointestinal symptom patterns. It may encourage researchers to assess whether gas-specific classification can improve understanding of heterogeneous digestive disorders.
However, clinical utility requires more than demonstrating different molecular profiles. A diagnostic test must provide information that influences appropriate patient management and improves decision-making. Researchers would need to establish whether identifying elevated hydrogen sulfide changes treatment selection, predicts response or improves clinical outcomes.
The American College of Gastroenterology and American Gastroenterological Association have recognised important limitations in conventional testing for small intestinal bacterial overgrowth. Breath testing is an indirect method, and results can be influenced by substrate choice, intestinal transit and other factors. Adding a third gas may provide more information, but it does not automatically resolve every source of diagnostic uncertainty.
The October announcement does not present a prospective trial comparing treatment guided by Trio-Smart with treatment based on conventional assessment. It also does not report improvements in abdominal pain, diarrhoea, quality of life or medication use attributable to three-gas testing. Those outcomes would be important for establishing whether expanded gas measurement produces additional clinical value.
For clinicians, the findings are most relevant as supporting evidence for considering microbial conditions separately during research and diagnostic evaluation. They do not justify treating one breath measurement as an independent diagnosis or assuming that all patients with elevated hydrogen sulfide require the same treatment.
What are the commercial implications for Gemelli Biotech’s Trio-Smart diagnostic platform?
Gemelli Biotech operates in the gastrointestinal diagnostics market, offering Trio-Smart and IBS-Smart through its laboratory services. IBS-Smart is a blood test associated with the investigation of post-infectious irritable bowel syndrome, while Trio-Smart measures three breath gases relevant to microbial fermentation. The products address different aspects of gastrointestinal assessment and should not be treated as interchangeable.
The company has reported serving more than 100,000 patients and healthcare providers through its testing services. This indicates an established commercial footprint, although the October announcement does not provide a breakdown of testing volumes, revenue or profitability by product. The new research could support scientific education and engagement with gastroenterology practices, but its direct commercial contribution cannot be quantified.
A noteworthy aspect of the research relationship is the connection between Gemelli Biotech and the investigators. Cedars-Sinai has a licensing agreement with the diagnostics company, and the study disclosed equity interests in Gemelli Biotech held by several participating researchers, including Mark Pimentel, Ali Rezaie and Ruchi Mathur. These relationships do not invalidate the findings, but they reinforce the value of independent replication.
Commercial adoption will also depend on how payers and clinicians evaluate the test’s utility. Demonstrating that hydrogen sulfide measurement provides additional biological information may strengthen the rationale for testing, but reimbursement decisions can require evidence that results affect patient management. The company has not announced a new coverage determination arising from the research.
The study was already published in June 2026, making the October 30 announcement a renewed presentation of existing peer-reviewed evidence rather than the release of a newly completed clinical trial. Its scientific significance rests on the quality of the original research and future validation, not the timing of the company announcement.
What evidence is needed before intestinal sulfide transcriptomics can guide personalised gastrointestinal treatment?
The next scientific requirement is independent validation of the reported gene-expression patterns in larger and more diverse patient populations. Researchers need to establish whether elevated hydrogen sulfide consistently corresponds with the same molecular pathways and whether the relationship remains reliable after accounting for other microbial conditions. Repeated measurements could also help determine the stability of these patterns over time.
Additional studies should examine whether changes in microbial composition, hydrogen sulfide production and intestinal gene expression occur together during treatment. Such investigations could help distinguish causal relationships from correlations. However, the choice of intervention would need to be supported by appropriate evidence rather than inferred solely from a breath test result.
Clinical studies could also assess whether gas-specific testing improves management compared with existing approaches. Relevant outcomes might include changes in symptoms, treatment response, quality of life and the avoidance of unnecessary interventions. These measures would provide a stronger foundation for evaluating routine diagnostic utility.
For Gemelli Biotech, the study contributes mechanistic evidence supporting the investigation of three-gas breath testing. It identifies a potentially meaningful relationship between hydrogen sulfide measurements and the biology of the intestinal lining. The decisive step will be demonstrating whether this additional information helps clinicians make better treatment decisions and improves outcomes for patients with difficult-to-classify gastrointestinal symptoms.
